Intuitive Surgical Inc. ISRG

Zacks Investment Research 13 nov

GE HealthCare Technologies announced the formation of the MAGNUS Neuro Alliance, a collaborative research network using its head-only 3.0T MR system to advance neuroscience research. The alliance will unite leading institutions for multi-site trials and research focused on developing MRI-based biomarkers for neurological diseases. GEHC stock declined 2.2% following the announcement, though the initiative could strengthen the company's position in advanced imaging and create long-term growth opportunities.

Zacks Investment Research 13 nov

AngioDynamics (ANGO) is gaining momentum from strong NanoKnife platform performance, with revenues surging 29% to $8.3 million in fiscal Q1 2027, driven by rising prostate procedure volumes and expanded regulatory approvals. The company's Med Tech segment continues robust growth with 13.2% year-over-year revenue increase, and management expects 12%-15% Med Tech revenue growth in fiscal 2027. However, tariffs and inflation remain headwinds despite recent tariff refunds improving margins.

Zacks Investment Research 13 nov

Abbott reported Q3 2026 sales growth of 14.5% to $13.01 billion with broad-based strength across Established Pharmaceuticals, Medical Devices, and Diagnostics segments. The company announced plans to separate its Nutrition business into an independent publicly traded company by end of 2027. However, Abbott narrowed its 2026 sales growth guidance to 6% from 6.5-7.5% due to headwinds in Electrophysiology and Diabetes Care segments. The stock has outperformed peers and sector benchmarks over the past six months but is rated a Hold.

Zacks Investment Research 13 nov

Hims & Hers has partnered with Eli Lilly to offer FDA-approved obesity treatments Zepbound and Foundayo through its digital health platform, with self-pay prices starting at $149-$299 monthly. The partnership aims to strengthen HIMS' position in the rapidly growing weight-loss market, though revenue impact depends on patient adoption and prescription volumes. The global obesity treatment market is projected to grow from $29 billion in 2026 to $60.5 billion by 2030.

Zacks Investment Research 13 nov

DexCom is well-positioned for growth driven by G7 15 Day adoption, international expansion, and manufacturing efficiencies that expanded Q3 gross margins to 65.1%. However, the company faces headwinds from PBM formulary risks, Ireland facility ramp-up costs, and rising R&D spending on G8 development. The stock has gained 22.6% year-to-date and maintains a Zacks Rank #3 (Hold) rating with improving 2026 earnings estimates.